Financial Data and Key Metrics Changes - Cryoport reported $41 million in revenue from continuing operations for Q1 2025, representing a 10% year-over-year growth and contributing to significant adjusted EBITDA improvement [10] - The company confirmed its revenue guidance for fiscal year 2025 in the range of $165 million to $172 million, indicating a 7.5% growth compared to fiscal year 2024 [13] Business Line Data and Key Metrics Changes - Life sciences services revenue increased by 17% year-over-year, driven by a 33% growth in support for commercial cell and gene therapies [10] - Life sciences services now account for 56% of total revenue, reflecting the increasing development and commercialization of cell and gene therapies [10] - The life sciences products business showed a 2% year-over-year growth, indicating demand stabilization [12] Market Data and Key Metrics Changes - Cryoport supported 19 commercial therapies and 711 clinical trials as of March 31, representing approximately 70% of cell and gene therapy trials [11] - The company anticipates up to 17 additional application filings and four therapy approvals for the remainder of 2025, indicating a robust pipeline [11] Company Strategy and Development Direction - The strategic partnership with DHL, involving the sale of Cryo PDP for an enterprise value of $195 million, is expected to enhance Cryoport's positioning in Asia Pacific and EMEA [12][13] - The partnership aims to leverage DHL's global scale and capabilities, allowing Cryoport to sharpen its focus on core life sciences service offerings in the regenerative medicine space [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth forecast despite potential tariff impacts, stating that they have taken steps to diversify the supply chain [14][15] - The company does not expect tariffs to significantly impact core support for clinical trials or commercial therapies [15] - Management remains optimistic about the commercial revenue ramp-up and the maturation of commercial therapies [44] Other Important Information - The company reported a significant increase in service gross margins year-over-year, with expectations for continued margin improvements [34] - The onboarding process for EntegraCell is progressing smoothly, with multiple commercial contracts already in place [65] Q&A Session Summary Question: Update on the launch of Entegrisel and client adoption - Management sees the market positively, with commercial revenue continuing to ramp and growth in clinical trials [20] Question: Contingent consideration impact on adjusted EBITDA - Management clarified that contingent consideration was backed out, and adjusted EBITDA improved significantly compared to Q1 of the previous year [29] Question: Response to potential tariffs and macro environment - Management indicated no significant tariff impact on cell and gene therapy, with continued commercial revenue growth [41][42] Question: Supply chain initiatives and margin improvements - Management stated that while they cannot quantify the impact of supply chain initiatives on margins, they expect strong gross margins to continue [54] Question: Impact of the new FDA director on therapy modalities - Management expressed optimism about the new FDA director's qualifications and the continued interest in cell and gene therapy [56] Question: Demand for new product launches - Management reported positive reception and ongoing adoption for new products, with expectations for substantial contributions in the future [62]

Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2025 was $10.4 million, down 8% from $11.3 million in the first quarter of 2024 [20][21] - Core revenue remained stable at $8.2 million, reflecting a slight increase of 1% year-over-year [21] - Gross margin decreased to 86% from 88% year-over-year, while non-GAAP adjusted gross margin remained stable at 83% [23] Business Line Data and Key Metrics Changes - Instrument revenue was $1.4 million, down from $1.9 million in the first quarter of 2024, impacted by cautious capital spending from customers [21][22] - License revenue was stable at $2.5 million, while processing assembly (PA) revenue increased to $3.9 million from $3.4 million year-over-year [21] - SPL program-related revenue was $2.1 million, down from $3.2 million in the first quarter of 2024 [22] Market Data and Key Metrics Changes - 57% of core revenue was derived from SPL customers, up from 53% in the first quarter of 2024, indicating a healthy balance of early-stage to clinical-stage customers [22] - The company noted a cautious environment for capital equipment purchasing decisions among customers, leading to some hesitance in capital expenditures [10][42] Company Strategy and Development Direction - The company is focused on executing its growth plan for 2025 and beyond, despite macro uncertainties [8][10] - MaxSite is committed to enhancing operational efficiency and making targeted investments to drive long-term returns [23][24] - The integration of SecureDx is progressing smoothly, allowing the company to expand its offerings in the cell and gene therapy space [12][51] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term health of the business, despite recent regulatory changes at the FDA [31][34] - The company anticipates continued strong demand in the cell and gene therapy market, with a focus on safety assessments [12][34] - Management reiterated guidance for core revenue growth of 8% to 15% for 2025, including at least $2 million from SecureDx [24][25] Other Important Information - The company is seeking shareholder approval to delist from AIM and maintain a single listing on NASDAQ [19] - MaxSite ended the first quarter with $174.7 million in cash equivalents and investments, with no debt [24] Q&A Session Summary Question: Regulatory changes and their impact - Management indicated that it is too early to assess the impact of recent FDA leadership changes, but they do not foresee any regulatory risks affecting their business [30][34] Question: Cost savings from operational review - The company expects to save approximately $100,000 annually from delisting, and has begun realizing savings from personnel reductions [35][36] Question: Changes in customer funding strategies - Management noted some constraints on capital expenditures but remains confident in their guidance for the year [42][43] Question: SecureDx acquisition integration - The integration is going well, with opportunities to expand into in vivo customers and complementary delivery systems [51][52] Question: SPL revenue performance - SPL revenue of $2.1 million exceeded expectations, with confidence in achieving the full-year guidance of $5 million [55][56] Question: Future product launches - The company has a robust product pipeline and plans to launch meaningful products this year [64][65] Question: Pipeline and portfolio management - Management noted a status quo in program rationalization among customers, with no significant expansion observed [71][73] Question: Revenue cadence for the year - Management is comfortable modeling incremental growth, particularly in the latter half of the year, based on identified opportunities [76][77]

Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2025 was $10.4 million, an 8% decline from $11.3 million in the first quarter of 2024 [20] - Core revenue remained stable at $8.2 million, showing a slight increase of approximately 1% year-over-year [21] - Gross margin decreased to 86% in Q1 2025 from 88% in Q1 2024, while non-GAAP adjusted gross margin remained stable at 83% [23] Business Line Data and Key Metrics Changes - Instrument revenue was $1.4 million, down from $1.9 million in Q1 2024, impacted by cautious capital spending from customers [21][22] - License revenue was stable at $2.5 million compared to $2.6 million in the prior year [21] - Processing assembly (PA) revenue increased to $3.9 million from $3.4 million year-over-year, indicating strong performance [21] Market Data and Key Metrics Changes - 57% of core revenue was derived from SPL customers in Q1 2025, up from 53% in Q1 2024, reflecting a healthy balance of early-stage to clinical-stage customers [22] - SPL program-related revenue was $2.1 million in Q1 2025, down from $3.2 million in Q1 2024, indicating variability in milestone revenue [22] Company Strategy and Development Direction - The company is focused on executing its growth plan for 2025 and beyond, adapting to macro uncertainties while maintaining operational focus [8][12] - MaxSite is committed to enhancing its product offerings and capital allocation initiatives, aiming for profitability with its existing balance sheet [10][18] - The integration of SecureDx is progressing smoothly, with expectations to deliver at least $2 million in revenue for the year [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term potential of the cell and gene therapy market, despite current market challenges [12][20] - The company is closely monitoring customer spending and expects cautious capital expenditure decisions to continue [11][44] - Management reiterated guidance for core revenue growth of 8% to 15% for 2025, assuming no significant changes in the operating environment [24][25] Other Important Information - The company announced plans to seek shareholder approval for delisting from AIM and maintaining a single listing on NASDAQ [19] - MaxSite finished Q1 2025 with total cash equivalents and investments of $174.7 million and no debt [24] Q&A Session Summary Question: Regulatory changes and their impact - Management indicated that recent FDA leadership changes have not raised concerns among customers regarding regulatory hurdles, maintaining confidence in the cell and gene therapy market [30][36] Question: Cost savings from operational review - The company expects to save approximately $100,000 annually from delisting and has begun realizing savings from personnel reductions [37][38] Question: Changes in customer funding strategies - Management noted some constraints on capital expenditure but remains confident in achieving annual guidance despite these challenges [42][44] Question: SecureDx acquisition integration - The integration of SecureDx is progressing well, with opportunities to expand into in vivo customer segments [50][52] Question: SPL revenue performance - SPL revenue of $2.1 million exceeded expectations, with management confident in achieving the full-year guidance of $5 million [55][56] Question: Future product launches - The company has a robust product pipeline and plans to launch new products this year, enhancing its total addressable market [63][65] Question: Pipeline and portfolio management - Management observed a status quo in program rationalization among customers, with no significant expansion noted [69][72] Question: Revenue cadence for the year - Management is comfortable modeling incremental growth in revenue, particularly in the latter half of the year, based on identified opportunities [73][75]

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][7] - The company is advancing off-the-shelf CAR-NK cell therapy programs for oncology, with its lead candidate SENTI-202 targeting acute myeloid leukemia (AML) [1][7] Clinical Development - SENTI-202 has shown promising initial clinical data, achieving minimal residual disease (MRD)-negative complete remissions in 2 out of 3 patients, with a durability of over 6 months as of March 20, 2025 [7] - Senti Bio's Gene Circuits have demonstrated functionality in T cells and the potential for selective targeting of solid tumors in preclinical studies [7] Communication and Investor Relations - The company has joined the Webull Corporate Connect Service platform to enhance communication with shareholders and investors, providing updates on corporate content such as news and earnings reports [3][4] - CEO Timothy Lu emphasized the importance of maintaining effective communication and increasing market awareness among investors [4] Strategic Partnerships and Future Directions - Senti Bio is actively pursuing partnerships to advance its capabilities in cell and gene therapy modalities beyond oncology [7] - The company aims to generate long-term value for stakeholders while continuing to execute on its clinical development plans [4][7]

Financial Data and Key Metrics Changes - As of December 31, 2024, the company had cash, cash equivalents, short-term investments, and restricted cash of $98.1 million, compared to $52.6 million as of December 31, 2023, indicating a significant increase in financial resources [24] - Research and development expenses were $34.4 million for the full year ended December 31, 2024, up from $31.1 million in 2023 [25] - General and administrative expenses rose to $29.9 million for the full year ended December 31, 2024, compared to $19 million in 2023, primarily due to commercial launch preparation costs [25][26] - The net loss for the full year ended December 31, 2024, was $63.7 million, or $1.55 loss per common share, compared to a net loss of $54.2 million, or $2.53 loss per common share in 2023 [26] Business Line Data and Key Metrics Changes - The company is preparing for the potential launch of PD Cell for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), with an estimated 750 RDEB patients in the U.S. who may be candidates for treatment [10][11] - The estimated cumulative revenue potential for PD Cell in the U.S. is over $2 billion, based on a conservative treatment cost of $1.5 million per patient [12] Market Data and Key Metrics Changes - The company anticipates activating treatment centers in the U.S. to begin patient biopsies approximately three months after the PDUFA date, with a gradual ramp-up in treatment capacity expected [7][16] - The payer mix indicates that 60-65% of lives are covered by commercial plans, 30-35% by Medicaid, and less than 10% by Medicare, highlighting the market access landscape [18] Company Strategy and Development Direction - The company is focused on securing FDA approval for PD Cell and launching it as a new treatment for RDEB patients, with significant growth potential anticipated in 2025 [76] - The strategy includes onboarding five treatment centers initially, with plans to gradually increase the number of centers as manufacturing capacity ramps up [70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming PDUFA date and the potential approval of PD Cell, which is expected to transform the treatment paradigm for RDEB patients [6][8] - The company is optimistic about the interest from payers and the clinical value of PD Cell, which addresses a significant unmet medical need in the RDEB treatment landscape [18] Other Important Information - The company has received a priority review designation from the FDA for PD Cell, which may qualify it for a Priority Review Voucher (PRV) upon approval [25][59] - The company is also exploring potential markets outside the U.S., including Europe and Asia, for future deployment of PD Cell [64][66] Q&A Session Summary Question: Is the FDA satisfied with the work done on the CMC side? - Management believes they have addressed all FDA requests from the previous CRL and have had multiple touchpoints with the agency, indicating a positive outlook [30][31] Question: What percentage of patients at the treatment centers may be eligible for PD Cell? - Approximately 30% of the estimated 750 RDEB patients are located in seven centers of excellence, with discussions ongoing about patient eligibility [34] Question: What is the primary reason for patients to seek PD Cell therapy? - The key reason is the need for durable wound closure, which significantly impacts the quality of life for patients with chronic wounds [37] Question: Will there be a patient backlog upon launch? - Management anticipates a patient backlog initially due to limited manufacturing capacity, which will gradually increase as production ramps up [44] Question: What is the company's strategy for physician education and patient awareness? - The company plans to engage in physician education and leverage advocacy groups to raise awareness within the tight-knit RDEB patient community [52][53]

Financial Data and Key Metrics Changes - ClearPoint Neuro reported total revenues of $31.4 million for the year ended December 31, 2024, representing a 31% increase from $24 million in 2023 [19] - Gross margin for the full year 2024 was 61%, up from 57% in 2023, primarily due to lower costs from transitioning to a new manufacturing facility and higher volumes [22] - Operational cash burn decreased to $9 million in 2024, a 35% reduction compared to 2023 [28] Business Line Data and Key Metrics Changes - Biologics and drug delivery revenue increased by 27% to $17.3 million in 2024, up from $13.6 million in 2023, driven by increased product sales as pharmaceutical partners advanced their development programs [20] - Neurosurgery navigation revenue grew 21% to $10.3 million in 2024, attributed to an increased installed base and the full market release of new systems [21] - Capital equipment and software revenue was $3.8 million for 2024, a 107% increase compared to 2023, as the installed base expanded [22] Market Data and Key Metrics Changes - The potential market for preclinical and clinical trial revenue for ClearPoint is approximately $300 million annually, with ClearPoint currently holding less than 10% of this market [41] - The cranial neuro navigation, laser therapy, and cranial drill markets represent approximately $200 million in annual opportunity, with ClearPoint currently capturing less than 10% [52] Company Strategy and Development Direction - ClearPoint is entering a phase called "Fast. Forward," focusing on leveraging its drug delivery ecosystem to support over 60 active biopharma partners [10][11] - The company aims to evolve its portfolio to enhance hospital efficiency and throughput, preparing for significant demand for new restorative therapies [12] - ClearPoint plans to expand its global installed base and pursue additional regulatory clearances in various countries, including Japan and Canada [57] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the expedited review processes from the FDA, which could lead to potential drug approvals in the next two years, significantly impacting revenue [66][70] - The company anticipates revenue growth between 15% and 31% for 2025, driven by core medical device business and the timing of preclinical GLP expansion [58][96] - Management emphasized a disciplined approach to managing expenses while exploring growth opportunities [82] Other Important Information - ClearPoint activated 25 new global customers in 2024, more than three times its historical average, indicating strong demand for its technology [55] - The company completed an equity offering in March 2024, raising net proceeds of $16.2 million, which strengthened its balance sheet and allowed it to retire all outstanding debt [29] Q&A Session Summary Question: Impact of fast-tracked assets on revenue - Management highlighted that expedited FDA processes could lead to drug approvals in the next two years, potentially adding approximately $250 million in revenue if just 1% of patients with certain disorders are treated [71] Question: Number of hospital sites needed for service - Management indicated that focusing on 200 to 250 hospitals capable of performing complex procedures would be ideal, aiming for 150 activated sites in the next three years [78] Question: 2025 guidance range explanation - Management explained that the wide guidance range is influenced by the timing of preclinical services scaling and the performance of the core medical device business, which is expected to grow faster than previous years [96]

Financial Data and Key Metrics Changes - Total revenue for 2023 was $143.3 million, an 11% decrease compared to 2022, with ex-COVID revenue decreasing 4% [10] - Q4 revenue was $32.7 million, representing a 26% year-over-year decrease, and a 23% decline when excluding COVID-related revenue from Q4 2022 [21] - Adjusted gross margin for Q4 was 35%, up from 32% in the prior year, primarily due to product mix and lower warranty expenses [23] - Adjusted operating loss for Q4 2023 was $9.3 million, compared to $8.2 million in Q4 2022 [25] - Adjusted EBITDA for Q4 2023 was $700,000, down from $1.7 million in the prior year but increased sequentially by $3.8 million from Q3 [26] Business Line Data and Key Metrics Changes - Cell processing platform revenue for 2023 declined 4% to $65.8 million, with a 6% decrease in biopreservation media revenue, partially offset by a 9% increase in other cell processing tools [10] - Biostorage and services platform revenue decreased 2% to $25.9 million, but grew 61% when excluding prior year COVID-related revenue [12] - Freezer and thaw platform revenue declined 23% to $15.1 million, primarily due to a difficult capital equipment environment [13] Market Data and Key Metrics Changes - The top 20 media customers accounted for 78% of media revenue, which was up slightly by 1% year-over-year [11] - Customers with commercially approved therapies accounted for an estimated 52% of direct media revenue in 2023, compared to 49% in 2022 [11] - The cell and gene therapy (CGT) industry is expected to grow at a 20% to 25% CAGR through 2033 [7] Company Strategy and Development Direction - The company is refocusing on higher margin recurring revenue streams and divesting freezer product lines to improve financial performance [6][14] - The company aims to leverage its market position in biopreservation media to drive adoption of other tools and services in its portfolio [89] - The 2024 revenue guidance is set between $95.5 million and $100 million, reflecting a cautious approach despite some optimism in market conditions [18] Management's Comments on Operating Environment and Future Outlook - Management noted that 2023 was a challenging year for the CGT industry, but there are early signs of stabilization and momentum [9] - The company expects a sustained recovery as 2024 progresses, with a focus on managing inventory normalization [9] - Management expressed confidence in the company's position to benefit from the growth of the CGT market, despite a cautious outlook for 2024 [89] Other Important Information - The company is in the process of divesting its freezer product lines, with two signed letters of intent (LOIs) and expects to close these transactions within 45 to 60 days [31][45] - The cash and marketable securities balance at December 31, 2023, was $52.3 million, up from $42.2 million at September 30, 2023 [27] Q&A Session Summary Question: Does the LOI allow the company to move the freezer assets to discontinued operations? - Management stated that a signed document is required to move them into discontinued operations, and they are working on finalizing the legal documents [31][32] Question: Can you discuss the steps taken to achieve positive EBITDA? - Management highlighted a reduction in force and control over discretionary expenses as key factors contributing to positive EBITDA [34][35] Question: How confident is the company about concluding the freezer sale? - Management expressed a 70% to 80% confidence level regarding the completion of the freezer sale within the expected timeframe [45][46] Question: What are the expectations for media revenue in 2024? - Management indicated that the first half of 2024 might be flat compared to the second half of 2023, with expectations of an uptake in the latter half [49] Question: What is the impact of the freezer business on adjusted EBITDA? - Management noted that they do not provide specific information on segment reporting but will clarify post-divestiture [81]

Table of Contents As filed with the Securities and Exchange Commission on April 26, 2023 Registration No. 333-269782 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Pre-effective Amendment No. 1 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (Primary Standard Industrial Classification Code Number) Delaware 2834 98-1465952 (I. ...